Biotech | February 27, 2022
HitGen completes research collaboration with MTPC
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying
he financing was significantly oversubscribed with high demand from both existing and new investors.
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
Subscribe To Our Newsletter & Stay Updated
